Towards an African-driven malaria vaccine development program: History and activities of the African Malaria Network Trust (AMANET)

American Journal of Tropical Medicine and Hygiene

Volumn 77, Issue SUPPL. 6, 2007, Pages 282-288

  Kilama, Wen L ^a   Chilengi, Roma ^a   Wanga, Charles L ^a  

^a African Malaria Network Trust   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

AFRICA; HUMAN; INTERNATIONAL COOPERATION; MALARIA; PARASITOLOGY; RESEARCH; REVIEW;

AFRICA; HUMANS; INTERNATIONAL COOPERATION; MALARIA; MALARIA VACCINES; RESEARCH;

EID: 40049104807     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2007.77.282     Document Type: Article

References (12)

1. UN Millennium Project, 2007. Millennium Development Goals (MDGs). Available at: http://www.unmillenniumproject.org/goals/index.htm. Accessed June 21, 2007.
2. Engers HD and Godal T, 1998. Malaria vaccine development: current status. Parasitol Today 14: 56-64.
3. The Abuja Declaration and the Plan of Action, 2007. An Extract from the African Summit on Roll Back Malaria, Abuja, 25 April 2000 (WHO/CDS/RBM/2000.17). Available at: www.rbm.who.int/docs/abuja-declaration.pdf. Accessed June 21, 2007.
4. P. Alonso, J. Sacarlal, J. Aponte, A. Leach, E. Macete, J. Milman, I. Mandomando, B. Spiessens, C. Guinovart, M. Espasa. Efficacy of the RTS,S/AS02A vaccine against infection and disease in young African children: synthesize controlled trial. Lancet 364 (Oct. 16):1411-1420.
5. Teuscher T, Schellenberg JR, Bastos de Azevedo I, Hurt N, Smith T, Hayes R, Masanja H, Silva Y, Lopez MC, Kitua A, 1994. SPf66, a chemically-synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission. Vaccine 12: 328-336.
6. Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C, 1994. Randomized trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344: 1175-1181.
7. Trust Deed AMANET. Available at: http://www.amanettrust.org/ext/news/ AMANET-Trust-Deed.pdf. Accessed June 21, 2007.
8. African Malaria Network Trust, 2007. Available at: http://www.amanet- trust.org/ext/reports/index.htm. Accessed June 21, 2007.
9. International Conference on Harmonization of Good Clinical Practice, 1996. Available at: http://www.ich.org/cache/compo/276-254-1.html. Accessed June 21, 2007.
10. Declaration of Helsinki, 2007. Available at: http://www.wma.net/e/policy/ b3.htm. Accessed on June 21, 2007.
11. European Malaria Vaccine Initiative, 2007. Available at: www.Emviorg.inforce.dk. Accessed on June 21, 2007.
12. Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, Derme AI, Diarra A, Ouedraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O, 2007. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 25: 2723-2732.